The clinical importance of IFNγ as an inflammatory mediator is evident; an anti-IFNγ antibody (Emapalumab) has been FDA approved for treating hemophagocytic lymphohistiocytosis, which is driven by IFNγ signaling (30). The gene discussed is IFNG; the disease is hemophagocytic syndrome.